Hans Biopharma: Positive Gene Therapy Data - Redeye
Redeye believes gene therapy is an interesting area for imlifidase. New data from its use as pre-treatment for patients with Crigler–Najjar syndrome who are immune to AAV support further development.
ANNONS
Redeye believes gene therapy is an interesting area for imlifidase. New data from its use as pre-treatment for patients with Crigler–Najjar syndrome who are immune to AAV support further development.
